Table 4.
Overview of the lymph node metastases rate of the included studies (n/N(%))
| LN station | T1 | T2 | T3 | T4 |
|---|---|---|---|---|
| Song et al | ||||
| 1 | 1/15 (6.7%) | 6/26 (23%) | 78/177 (44.1%) | 43/110 (39.1%) |
| 2 | 1/15 (6.7%) | 4/26 (15.4%) | 54/177 (30.5%) | 36/110 (32.7%) |
| 3 | 2/15 (13.3%) | 6/26 (23.1%) | 70/177 (39.5%) | 57/110 (51.8%) |
| 4 | 0/15 | 1/26 (3.9%) | 24/177 (13.9%) | 23/110 (20.9%) |
| 5 | 0/15 | 1/26 (3.9%) | 12/177 (6.8%) | 13/110 (11.8%) |
| 6 | 0/15 | 1/26 (3.9%) | 13/177 (7.3%) | 14/110 (12.7%) |
| 7 | 0/15 | 3/26 (11.5%) | 40/177 (22.6%) | 32/110 (29.1%) |
| 8 | 0/15 | 2/26 (7.7%) | 14/177 (7.9%) | 17/110 (15.4%) |
| 9 | 0/15 | 0/26 | 10/177 (5.6%) | 7/110 (6.4%) |
| 10 | 0/15 | 0/26 | 16/177 (9%) | 13/110 (11.8%) |
| 11 | 0/15 | 2/26 (7%) | 10/177 (5.6%) | 15/110 (13.6) |
| 12 | 0/15 | 1/26 (3.9%) | 7/177 (4%) | 9/110 (8.2%) |
| 13 | 1/177 (0.6%) | 3/110 (2.7%) | ||
| 14 | 3/177 (1.7%) | 4/110 (3.6%) | ||
| 15 | 0/177 | 2/110 (1.8%) | ||
| 16 | 4/177 (2.3%) | 11/110 (10.0%) | ||
| 19 | 0/26 | 1/177 (0.6%) | 1/110 (0.9% | |
| 20 | 0/26 | 0/177 | 1/110 (0.9% | |
| Total | 2/15 (13.33%) | 12/26 (46.2%) | 129/177 (72.9%) | 88/110 (80%) |
| Han et al | ||||
| 1 | 6/650 (0.9%) | |||
| 2 | 1/650 (0.2%) | |||
| 3 | 44/650 (6.8%) | |||
| 4 | 23/650 (3.5%) | |||
| 5 | 1/650 (0.2%) | |||
| 6 | 18/650 (2.8%) | |||
| 7 | 4/650 (0.6%) | |||
| 8 | 3/650 (0.5%) | |||
| 9 | 4/650 (0.6%) | |||
| 10 | 0/650 | |||
| 11 | 1/650 (0.2%) | |||
| 64/650 (9.8%) | ||||
| Kong et al | ||||
| 1 | 3/643 (0.5%) | 9/131 (6.9%) | 10/175 (5.7%) | 6/92 (6.5%) |
| 2 | 0/20 | 0/1 | 0/10 | 0/13 |
| 3 | 29/650 (4.5%) | 18/131 (13.7%) | 78/176 (44.3%) | 61/93 (65.6%) |
| 4 | 19/650 (2.9%) | 16/131 (12.2%) | 46/176 (26.1%) | 54/93 (58.1%) |
| 5 | 8/627 (1.3%) | 11/124 (8.9%) | 25/172 (14.5%) | 27/88 (30.7%) |
| 6 | 30/650 (4.6%) | 32/131 (24.4%) | 65/176 (36.9%) | 54/92 (58.7%) |
| 7 | 16/649 (2.5%) | 14/129 (10.9%) | 36/176 (20.5%) | 29/93 (31.2%) |
| 8 | 10/637 (1.6%) | 13/129 (10.1%) | 35/172 (20.3%) | 27/92 (29.3%) |
| 9 | 0/601 | 1/126 (0.8%) | 6/165 (3.6%) | 9/86 (10.5%) |
| 10 | 0/15 | 0/3 | 1/11 (9.1%) | 1/8 (12.5%) |
| 11 | 4/572 (0.7%) | 3/120 (2.5%) | 7/158 (4.4%) | 15/86 (17.4) |
| 12 | 3/425 (0.7%) | 7/109 (6.4%) | 7/149 (4.7%) | 10/76 (13.2) |
| 14 | 1/271 (0.4%) | 3/101 (3.0%) | 4/133 (3.0%) | 8/76 (10.5%) |
| Namieno et al | ||||
| 1 | 7/1137 (0.6%) | |||
| 2 | 1/1137 (0.1%) | |||
| 3 | 60/1137 (5.3%) | |||
| 4 | 37/1137 (3.3%) | |||
| 5 | 4/1137 (0.4%) | |||
| 6 | 24/1137 (2.1%) | |||
| 7 | 12/1137 (1.1%) | |||
| 8 | 6/1137 (0.5%) | |||
| 9 | 7/1137 (0.6%) | |||
| 14 | 1/1137 (0.1%) | |||
| Total | 108/1137 (9.5%) | |||
| Maruyama et al | ||||
| 1 | 16/328 (4.9%) | 326/1371 (23.8%) | ||
| 2 | 7/328 (2.1%) | 233/1371 (17.0%) | ||
| 3 | 82/328 (25.0%) | 1000/1371 (72.9%) | ||
| 4 | 52/328 (15.9%) | 609/1371 (44.4%) | ||
| 5 | 7/328 (2.1%) | 115/1371 (8.4%) | ||
| 6 | 56/328 (17.1%) | 472/1371 (34.4%) | ||
| 7 | 30/328 (9.1%) | 504/1371 (36.8%) | ||
| 8 | 23/328 (7.0%) | 399/1371 (29.1%) | ||
| 9 | 16/328 (4.9%) | 280/1371 (20.4%) | ||
| 10 | 3/328 (0.9%) | 120/1371 (8.8%) | ||
| 11 | 7/328 (2.1%) | 193/1371 (14.1%) | ||
| 12 | 7/328 (2.1%) | 115/1371 (8.4%) | ||
| 13 | 0/328 | 37/1371 (2.7%) | ||
| 14 | 0/328 | 55/1371 (4.0%) | ||
| 15 | 0/328 | 9/1371 (0.7%) | ||
| 16 | 0/328 | 115/1371 (8.4%) | ||